IDL Diagnostics (IDLDX) Q3 2024 earnings summary

Executive summary

• Achieved positive net earnings excluding goodwill amortization in Q3 2024, signaling progress toward long-term profitability.

• Revenue grew 31% year-over-year for the quarter and 25% for the nine-month period, driven by strong sales in bacteriology and oncology segments.

• Strategic review underway to focus on growth and business development, supported by a strong cash position for potential in-licensing or acquisitions.

• Production running at full capacity with ongoing efforts to scale up to meet increasing demand.

Financial highlights

• Q3 2024 net sales: KSEK 13,996 (up from 10,700); nine-month net sales: KSEK 42,072 (up from 33,528).

• Q3 profit after financial items: KSEK -9,841 (improved from -13,003); nine-month profit: KSEK -33,437 (improved from -42,161).

• Q3 EBITDA (excluding goodwill amortization): just over KSEK 160; net earnings (excluding goodwill): just over KSEK 50.

• Q3 EPS: SEK -0.04 (vs. -0.06); nine-month EPS: SEK -0.15 (vs. -0.18).

• Cash and cash equivalents at period end: KSEK 44,535 (vs. 51,512).

Outlook and guidance

• Continued strong order intake and accelerated sales growth expected to support future performance.

• Company aims to expand product portfolio through acquisitions or in-licensing, leveraging strong cash position.

• Market for cancer diagnostics projected to grow significantly, with AroCell positioned to benefit from demand for patient-friendly, cost-effective tests.